Teduglutide (GLP2 2G) HGDGSFSDEMNTILDNLAARDFIN-W-LIQTKITD-acid

Description

Teduglutide is a GLP-2 analogue, in which the alanine at position 2 has been substituted with glycine making the peptide resistant to degradation by dipeptidyl peptidase-4 (DPP-4).  Teduglutide therefore has a longer half-life than GLP-2 (2-3 hours for Teduglutide vs 7 min for GLP-2). Teduglutide has high bioavailability after subcutaneous administration, suggesting that teduglutide has enhanced biological activity, relative to native GLP-2.

GLP-2 is a gut hormone produced in the enteroendocrine L cells of gastrointestinal tract by the cleavage of the 160-amino-acid proglucagon molecule. GLP-2 is secreted following the ingestion of food and carries out its activities via the GLP-2 G-protein coupled receptors (GLP-2Rs). GLP-2 has a range of roles within the cell, including: anti-inflammatory effects; promoting the expansion of the intestinal mucosa; stimulating intestinal blood flow; inhibiting gastric acid secretion and gastric emptying; increasing intestinal barrier function and enhancing nutrient and fluid absorption

Application Data

GLP-2 analogue, resistant to peptidase degradation. Enhanced biological activity relative to native GLP-2

Teduglutide (GLP2 2G) 0.5mg

$225.00
Datasheet download

Teduglutide (GLP2 2G) 1mg

$300.00
Datasheet download
Secure payments
Please click here to download Material Safety Datasheet (MSDS)
Catalogue number crb1000390
Sequence (one letter code) HGDGSFSDEMNTILDNLAARDFIN-W-LIQTKITD-acid
Sequence (three letter code) H-His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-OH
Purity >95%
Molecular Weight 3749.8
References

Jeppesen, P. (2012). Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Ther Adv in Gastroenterol, 5(3), 159-171. PMID: 22570676

Schwartz, L., O’Keefe, S., Fujioka, K., Gabe, S., Lamprecht, G., Pape, U., Li, B., Youssef, N. and Jeppesen, P. (2016). Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clin and Transl Gastroenterol, 7(2), e142-e142. PMID: 26844839

Teduglutide is a GLP-2 analogue, in which the alanine at position 2 has been substituted with glycine making the peptide resistant to degradation by dipeptidyl peptidase-4 (DPP-4).  Teduglutide therefore has a longer half-life than GLP-2 (2-3 hours for Teduglutide vs 7 min for GLP-2). Teduglutide has high bioavailability after subcutaneous administration, suggesting that teduglutide has enhanced biological activity, relative to native GLP-2.


GLP-2 is a gut hormone produced in the enteroendocrine L cells of gastrointestinal tract by the cleavage of the 160-amino-acid proglucagon molecule. GLP-2 is secreted following the ingestion of food and carries out its activities via the GLP-2 G-protein coupled receptors (GLP-2Rs). GLP-2 has a range of roles within the cell, including: anti-inflammatory effects; promoting the expansion of the intestinal mucosa; stimulating intestinal blood flow; inhibiting gastric acid secretion and gastric emptying; increasing intestinal barrier function and enhancing nutrient and fluid absorption